Clinical trials: Patency Rate
Lung Cancer
Study to See if Microcoil Insertion Reduces the Rate of Open Thoracotomy for Removal of Lung Nodules
LAY ABSTRACT 1. Statement of the health problem or issue: Of the estimated 24,000 Canadians who will be diagnosed with lung cancer in 2008, 21,000 will die of their disease.
- Trial name
- NCT01028417
- Testing
- Platinum microcoil
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Hepatitis C, Chronic
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin)…
- Trial name
- NCT01585324
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Asthma
A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.
In relation to their severity, hepatic diseases can significantly modify drug absorption and disposition and consequently can interfere with drug efficacy and/or produce toxicity.
- Trial name
- NCT01266941
- Testing
- Inhaled FF 200mcg/GW642444M 25mcg
- Where
- 3 sites in Czechia, Slovakia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Side Effect of Drug
Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate
Psilocin is the active metabolite of psilocybin a natural material found in several types of fungi. The bioavailability of psilocybin, the prodrug of psilocin, has been reported to be over 60%.
- Trial name
- Psilocin-1 (NCT06035900)
- Testing
- Psilocin
- Where
- Jordan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lobe Sciences Ltd.
Pulmonary Disease, Chronic Obstructive
Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs
For effective drug delivery using inhalation route, it is important to use the inhalers correctly. This open-label study will evaluate the error rates during the use of ELLIPTA DPI, alone or in combination, in comparison with…
- Trial name
- NCT03114969
- Testing
- Relvar ELLIPTA, Symbicort TURBUHALER, Seretide DISKUS
- Where
- 13 sites in Netherlands, United Kingdom
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Kidney Disease, Albuminuria
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
Patients with chronic kidney disease (CKD) and albuminuria are at increased risk of developing cardiovascular disease (CVD) which is often associated with hypertension, left ventricular hypertrophy, endothelial dysfunction and…
- Trial name
- NCT00625820
- Testing
- 6R BH4, Vitamin C
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Healthy Volunteers
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
- Trial name
- NCT05283694
- Testing
- risankizumab
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AbbVie
Pulmonary Disease, Chronic Obstructive, Asthma
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of Berodual delivered via the…
- Trial name
- NCT00153075
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Unresected Stage IIIb to IVM1c Melanoma
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to…
- Trial name
- TVEC-325 (NCT02366195)
- Testing
- Talimogene Laherparepvec
- Where
- 42 sites in United States, Austria and 11 more
- Volunteers
- 112 people
- Sponsor
- Amgen
Chronic Myeloid Leukemia
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully.
- Trial name
- NCT04043676
- Testing
- Ponatinib
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundación Teófilo Hernando, Spain
Chronic Myelogenous Leukemia
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
- Trial name
- NCT04948333
- Testing
- ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD
- Where
- 48 sites in Argentina, Austria and 14 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Female Infertility
Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Our study aims to describe the effect of the intrauterine adminstration of HCG versus the endometrial injury by pipelle on the ongoing pregnancy rate and the biochemical pregnancy rate in women with unexplained infertility…
- Trial name
- NCT05050747
- Testing
- HCG is introduced at day of trigger intra-uterine, endometrial injury by pipelle
- Where
- Egypt
- Volunteers
- 402 people
- Sponsor
- Wael Elbanna Clinic
Jaw, Edentulous, Partially
Study on OsseoSpeed™ Implants in Patients Missing 2-5 Teeth in the Posterior Lower Jaw, Restored With Permanent Teeth Attached 6-7 Weeks Later
The purpose of the study is to evaluate Astra Tech Dental Implant System, Fixture Osseospeed™, in patients with tooth loss in the posterior mandible in an early loading protocol.
- Trial name
- NCT00711425
- Testing
- OsseoSpeed™
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Helicobacter Pylori Infection
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
The purpose of this study was to evaluate the efficacy and safety of vonoprazan with different doses of amoxicillin for Helicobacter Pylori.
- Trial name
- NCT05649540
- Testing
- Vonoprazan, Amoxicillin
- Where
- 13 sites in China
- Volunteers
- 900 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Cervical Adenocarcinoma, Stage IB Cervical Cancer
Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer
This prospective phase II trial study aims to optimize the increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose…
- Conditions
- Cervical Adenocarcinoma, Stage IB Cervical Cancer, Stage II Cervical Cancer, Stage III Cervical Cancer
- Trial name
- TRIDICOL (NCT02880007)
- Testing
- External Beam Radiation Therapy, PDR Brachytherapy, Cisplatin
- Where
- 9 sites in France
- Volunteers
- 48 people
- Sponsor
- Institut de Cancérologie de Lorraine
Anastomotic Leak, Colon Cancer
Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy
The primary aim of the study is to show that the ileo-colic anastomosis leakage rate until the first 30 days after surgery using MonoPlus® suture material for anastomosis construction after right hemicolectomy is not inferior to…
- Conditions
- Anastomotic Leak, Colon Cancer, Right Hemicolectomy
- Trial name
- LICOSARH (NCT07132970)
- Testing
- Monoplus Suture Material
- Where
- 4 sites in Germany
- Volunteers
- 249 people
- Sponsor
- Aesculap AG
Chronic Hepatitis B, Roadmap Concept in Chronic Hepatitis B Treatment
Efficacy Study of Telbivudine in Chronic Hepatitis B Patients
This study is designed to support the optimal use of telbivudine by providing data to refine our understanding of telbivudine efficacy and resistance in real life clinical setting in patients with chronic hepatitis B with defined…
- Conditions
- Chronic Hepatitis B, Roadmap Concept in Chronic Hepatitis B Treatment, 24-week PCR Negativity of Telbivudine, PCR Negativity at 52 and 104 Week
- Trial name
- NCT01958229
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- National Taiwan University Hospital
Epidural; Anesthesia
Does Ultrasound Increase the First-pass Success of Epidural Space Identification in Obese Parturients
Obesity is associated with difficulties in epidural space catheterization. The investigators want to prove that a pre-procedural ultrasound exam of lumbar spine increase the first-pass success rate of the epidural space…
- Trial name
- NCT04352283
- Testing
- Preprocedural ultrasound exam of lumbar spine
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Caen
Healthy, Bioavailability
Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative…
- Trial name
- NCT01136551
- Testing
- Huperzine A
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization